Skip to content
Sign in

Business opportunities

Who each startup should sell to, sell through, build with, enter a market with or raise from, read from the whole network. Every opportunity comes with its reasoning, the evidence and a first step.

SWC 2026 Finalist

BILIX

KAIST spin-off developing PEGylated bilirubin BX-001N to prevent acute kidney injury after cardiac surgery, now in phase 2a in Korea.

Open the dossier
Opportunities
4
High confidence
070% and above
Counterparts
4startups and investors
  • Customers 1
  • Investors 2
  • Peers 1

Customers1

Who could buy, or sell through

Buy Latin American real-world data to design phase 2b/3 and select sites

Phase 2b/3 design needs AKI incidence after cardiac surgery, baseline risk and site volumes. Cromodata's hospital network in five Latin American countries can supply de-identified cohorts and identify high-volume sites. Bilix gets cheaper trial design and new geographies; Cromodata gets a named pharma-type buyer.

30%confidence

Evidence from the records

  • “Marketplace in operation: claimed network of 47 to 84+ healthcare facilities in 5 countries (Argentina, Uruguay, Mexico, Dominican Rep., Brazil); no data buyer publicly named.”
  • “BX-001N: phase 1 completed (51 volunteers, Australia), phase 2a under way in Korea (NCT07164833) with KDDF support.”
If it works
A feasibility dataset and shortlisted LatAm sites for later trials.
First step
Send Cromodata a cohort definition (cardiac surgery, creatinine follow-up) and request a feasibility count.

Investors2

A fund whose thesis fits

Approach Sands Capital for the Series C, via PolyJoule

Sands Capital invests at Series A and later in biotech and medtech globally, matching Bilix's late-private stage. It is reported as an investor in PolyJoule in the network.

20%confidence

Evidence from the records

  • “Sands Capital Ventures and others (according to aggregators)”
  • “High risk: phase 2 clinical risk and large funding needs despite US$13M raised.”
If it works
A global growth-stage biotech investor for the post-phase-2a round.
First step
Ask PolyJoule's CEO for an intro to Sands Capital's life-science team.

Pitch EFung Capital, Pleryon's biotech investor

EFung invests at Series A and later in biotech in China and globally and backed Pleryon Therapeutics in the network; an Asian investor fits a Korean asset seeking regional licensing.

20%confidence

Evidence from the records

  • “EFung Capital (cited by CB Insights and Caplight); other historical investors: Zero2IPO, Kaitai Capital, Lapam Capital, HKUST R&D Corporation”
  • “Successful phase 1”
If it works
Capital plus access to Chinese licensing partners.
First step
Ask Pleryon's team for an intro to EFung Capital.

Peers1

Founders solving the same problem elsewhere

Exchange on polymer-drug CMC and Asian licensing

Both companies develop polymer-based therapeutics at Series A in Asia. Sharing CMC suppliers, regulatory strategy and licensing contacts reduces cost and time for both.

20%confidence

Evidence from the records

  • “Proprietary platforms for designing and controlling the structure of large synthetic and modified natural polymers, for drug delivery and injectable biomaterials.”
  • “PEGylated bilirubin nanomedicine platform (antioxidant and immunomodulatory activity)”
If it works
Shared vendor lists and licensing introductions.
First step
Arrange a CEO call during the Grand Finale.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai

Most promising across the network

587 opportunities analysed
  1. Critical Medical DeviceswithLove LifesciencesPeers

    Share drug-delivery device lessons with Love Lifesciences

    Both are US pre-seed drug-delivery device companies founded around a clinical pain point. Exchanging contract manufacturer, regulatory consultant and pharma-partnering contacts saves both time and money.

    30%
  2. Roam TechnologieswithByonyksPeers

    Learn from Byonyks' 2025 FDA class II clearance and US launch set-up

    Byonyks obtained FDA 510(k) clearance for a home-therapy device and is setting up US infrastructure, the exact path Roam must follow. A founder exchange can shorten Roam's regulatory and DME launch planning.

    30%
  3. Lampsy HealthwithLegit.HealthPeers

    Learn from Legit.Health's medical-device certification path

    Legit.Health took an AI medical device through CE marking with an ISO 13485 quality system in Iberia; Lampsy faces the same regulatory steps. A founder exchange shortens the learning curve.

    30%
  4. AlgatekwithAtoz Carbon Cycle PlatformPeers

    Regional microalgae alliance for Malaysia

    Atoz builds nature-based carbon solutions with microalgae in Malaysia but has no public traction; Algatek has installed units at Indonesian SOEs. Sharing technology, MRV methods and possibly licensing Algatek units into Malaysia would give both a bigger regional story.

    25%
  5. Atoz Carbon Cycle PlatformwithAlgatekPeers

    Learn from a deployed microalgae business next door

    Algatek has leased microalgae units to Indonesian SOEs and claims IoT-monitored capture; Atoz has a prototype. Licensing or co-selling Algatek's MicroForest in Malaysia could give Atoz an immediate product while it builds its platform.

    25%
  6. Love LifescienceswithCritical Medical DevicesPeers

    Share FDA and QMS learnings between two pre-clearance drug-delivery devices

    Both companies are pre-FDA drug-delivery device makers founded by clinicians. Sharing regulatory consultants, QMS templates and test labs reduces cost for both.

    25%
  7. ZymoChemwithYeast Bay BioPeers

    Davis fermentation network and scale-up playbook

    ZymoChem's CEO trained at UC Davis, where Yeast Bay Bio was founded in 2025. Sharing contract-fermentation contacts, scale-up lessons and DOE/grant experience is low cost and high value for a seed-stage fermentation company.

    25%
  8. LainTechwithBaniqlPeers

    Battery-metals alliance between two atmospheric leaching processes

    Baniql produces battery-grade nickel MHP from Indonesian laterites at low temperature and pressure; Lain Tech treats sulfides containing cobalt and nickel. Together they can present battery offtakers a complementary low-carbon hydrometallurgy portfolio and share know-how on catalysts and scale-up.

    25%
  9. Amass BiosystemswithRegenratePeers

    Borrow Regenrate’s contract-farming model for intercrops

    Regenrate monetises the intercrop period in France with free seed and guaranteed purchase prices — the same farmer-economics problem Amass must solve. Its contract design is a template for Amass' farmer offer.

    20%
  10. BILIXwithPleryon TherapeuticsPeers

    Exchange on polymer-drug CMC and Asian licensing

    Both companies develop polymer-based therapeutics at Series A in Asia. Sharing CMC suppliers, regulatory strategy and licensing contacts reduces cost and time for both.

    20%
  11. Pleryon TherapeuticswithBioSapienPeers

    Compare local-delivery regulatory playbooks

    Both companies build localised, extended-release delivery platforms (BioSapien in oncology implants, Pleryon in ophthalmology). Sharing regulatory and CMC learnings on biodegradable delivery systems reduces costly missteps.

    20%
  12. RegenratewithAmass BiosystemsPeers

    Exchange intercrop-for-bioenergy playbooks

    Amass grows a bioenergy crop alongside corn for biomass; Regenrate grows camelina between crops for biofuel. Both sell farmer income diversification to energy buyers and can share off-take and agronomy learnings across EU/US.

    20%
  13. FluvwithTausiPeers

    Share the gig-provider OS playbook

    Tausi runs an AI-powered operating system for independent beauticians with verified providers and a commission model. Fluv faces the same supply-side problem with pet-sitters; exchanging verification, training and retention practices is useful for both.

    15%
  14. PromptendwithNeurath AIPeers

    AI reliability peer exchange

    Both address trust in AI outputs (Promptend for generated code, Neurath for model predictions) and sell to risk-averse engineering buyers; sharing go-to-market learnings on assurance products is useful.

    15%
  15. PsychoTechwithPromptendPeers

    Moldovan finalist cohort coordination

    Both represent Moldova at the SWC final; pooling travel, investor meetings and Startup Moldova support reduces cost, and PsychoTech could pilot Promptend on its client code.

    15%
  16. ShopperoowithPardon AIPeers

    Benchmark against Pardon AI's profitability agents

    Pardon AI sells AI agents that optimise revenue and margins for retail and food service and has been through Techstars. A founder exchange clarifies positioning and possible specialisation (pricing/assortment vs broader profitability).

    15%
  17. VIEROC AIwithWiseUnitPeers

    Exchange voice-agent and chat-agent learnings with WiseUnit

    WiseUnit sells an AI phone receptionist; VIEROC focuses on chat agents. Comparing pricing, churn and model costs, or white-labelling each other's channel, could help both small teams.

    15%
  18. SchoolACEwithKetzaiPeers

    Learn from Ketzai’s path to 40,000 teachers

    Ketzai solved teacher acquisition for AI lesson planning by aligning with official curricula; SchoolACE can learn its playbook and potentially share content tooling for Spanish-speaking US classrooms.

    15%

Similar profiles

Compatibility score with BILIX

Scored on needs and offers, market bridge, customer potential, sector synergy and stage. Open a profile to see each dimension.